Form 4: Inmune Bio CSO's Stock Options Repriced to $1.50

Inmune Bio, Inc. repriced Chief Scientific Officer Mark William Lowdell's stock options to an exercise price of $1.50 per share.

Summary

• Inmune Bio, Inc. (INMB) repriced a total of 924,000 outstanding stock options held by Chief Scientific Officer Mark William Lowdell.
• The exercise price for these options was reduced to $1.50 per share, matching the closing price of the Issuer's common stock on The Nasdaq Capital Market on the repricing date.
• The repricing, effective November 18, 2025, was approved by the Issuer's stockholders.
• The repriced options were originally granted under the 2017 Stock Incentive Plan, 2019 Stock Incentive Plan, and Second Amended and Restated 2021 Stock Incentive Plan.
• Original exercise prices for the repriced options ranged from $3.91 to $9.92 per share.
• All other terms and conditions of the repriced options, including vesting schedules and term, remain unchanged.

Sentiment

Score: 4

Explanation: The repricing is positive for the executive's incentive and retention but carries negative implications for existing shareholders due to potential future dilution and the underlying signal of past stock underperformance. The stockholder approval mitigates some governance concerns but doesn't erase the negative implications of the stock's trajectory.

Positives

• The repricing significantly lowers the exercise price for 924,000 stock options held by the Chief Scientific Officer, making them more 'in-the-money' and increasing their potential value to the executive.
• This action can serve as a retention mechanism, incentivizing the Chief Scientific Officer to remain with the company and contribute to future growth, especially if the stock price has underperformed.

Negatives

• The repricing of options to a lower exercise price suggests that the company's stock price has significantly declined since the original grant dates, indicating past underperformance.
• While not directly dilutive at the time of repricing, the lower exercise price makes it more likely that these options will be exercised, potentially leading to future dilution for existing shareholders.
• Option repricing can be viewed negatively by investors as it often transfers value from shareholders to executives, particularly if not accompanied by strong performance improvements.

Risks

• Potential for shareholder dissatisfaction due to the perceived transfer of value from shareholders to executives through option repricing.
• The repricing may signal a lack of confidence in the company's ability to reach the original, higher exercise prices, which could impact investor sentiment.
• Future stock price appreciation might be partially offset by the increased likelihood of option exercise and subsequent dilution.

Future Outlook

The repricing of stock options, while making them more attractive to the executive, implies a need to re-incentivize management following a period where the stock price has fallen below previous grant prices. The continued vesting of these options is contingent on the Chief Scientific Officer's ongoing service to the Issuer.

Management Comments

• Effective as of November 18, 2025, the Issuer's stockholders approved a one-time repricing of certain outstanding stock options granted under the 2017, 2019, and 2021 Stock Incentive Plans.
• The per share exercise price of each repriced option was reduced to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date.
• Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including vesting and term, remain in full force and effect.
• Stock option awards become exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported, subject to the Reporting Person's continued service with the Issuer.

Industry Context

Stock option repricing is a practice sometimes employed by companies, particularly in sectors like biotechnology where stock volatility can be high, to re-incentivize executives when the company's stock price has significantly declined, rendering previously granted options 'underwater' (i.e., their exercise price is higher than the current market price). While it can be a tool for executive retention, it often raises corporate governance concerns among investors.

Comparison to Industry Standards

• Option repricing, while not uncommon, is generally viewed less favorably by corporate governance advocates compared to other compensation strategies, as it can dilute shareholder value and reward executives despite stock underperformance.
• Companies like Zynga (2012) and Groupon (2012) have faced investor scrutiny for similar repricing actions, often signaling a need to re-align executive incentives after significant stock price drops.
• Best practices often suggest linking executive compensation more directly to long-term performance metrics rather than repricing options, which can be seen as a short-term fix for retention issues.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, and a signal of past stock underperformance. May raise governance concerns.
• Employees (specifically Mark William Lowdell): Increased incentive and retention due to more valuable stock options.

Next Steps

• The repriced stock options will continue to vest according to their original schedules, contingent on Mark William Lowdell's continued service with Inmune Bio, Inc.

Key Dates

Recommendation

The repricing of executive stock options is a mixed signal. While it aims to retain key talent like the Chief Scientific Officer by making their incentives more valuable, it also reflects a significant decline in the company's stock price since the original grants. This action, though stockholder-approved, can be viewed as dilutive and may raise questions about corporate governance and accountability for past performance. Investors should 'hold' to assess whether this re-incentivization leads to improved future performance and stock appreciation, outweighing the potential dilution and negative sentiment associated with repricing.

Keywords

Inmune Bio, INMB, Stock Option Repricing, Executive Compensation, Form 4, Mark William Lowdell, Chief Scientific Officer, Corporate Governance